OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

Related Articles

Immunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentum

4 months ago

Allbirds' $39 Million Sale: A Cautionary Tale for the IPO Class of 2021

7 months ago

Enliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Check

3 months ago

Is Enliven Therapeutics (ELVN) a Buy After Its Upsized Offering and Positive Clinical Data

4 months ago

Category

You may also like

Stock News•3 weeks ago

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotech stocks are rebounding as pharma M&A hits record highs to counter patent cliffs, though retail investors remain skeptical.

ABBV

Share

Stock News•2 months ago

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million, with $75 million funded upfront and $325 million tied to milestones, providing strategic flexibility thr...

NTLA

Share

Stock News•2 months ago

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Enliven Therapeutics holds $895M cash, funding operations into 2030, after Phase 1 data showed 61% MMR at 80 mg daily for ELVN-001 in chronic myeloid leukemia, supporting earlier-line potential.

ELVN

Share